MAZZARINO v. ADMA BIOLOGICS, INC.

What this case is about

Investors are suing ADMA Biologics, a pharmaceutical company, alleging that the company and its executives made false or misleading statements to the investing public in violation of federal securities laws. The plaintiffs claim that ADMA Biologics misled investors about material aspects of its business, financial condition, or operations, causing the company's stock price to be artificially inflated. When the truth allegedly came to light, the stock price dropped, causing financial harm to shareholders. The proposed class consists of investors who purchased ADMA Biologics securities during a specific time period and suffered losses as a result of the alleged misrepresentations. The lawsuit seeks to recover damages on behalf of all affected shareholders.

What happens next

The case is in its earliest stage. The defendant has not yet responded. Class certification — the court's decision on whether the case can proceed as a class action — typically takes 12 to 24 months after filing.

Source: CourtListener docket entry. This summary was generated automatically and may not reflect subsequent filings.